BioCentury
ARTICLE | Company News

Cangene, Emergent BioSolutions deal

March 3, 2014 8:00 AM UTC

Biodefense company Emergent completed the acquisition of Cangene for $3.24 per share in cash or $222 million in cash (see BioCentury, Dec. 16, 2013). ...